Cancer immunotherapy by fusions of dendritic and tumour cells and rh‐IL‐12 - Concepedia

Concepedia

Publication | Closed Access

Cancer immunotherapy by fusions of dendritic and tumour cells and rh‐IL‐12

32

Citations

26

References

2005

Year

Sadamu Homma, Tetsuro Kikuchi, N. Ishiji, Kazuhiko Ochiai, Hiroshi Takeyama, Hideo Saotome, Yukiko Sagawa, Eiichi Hara, Donald Küfe, John L. Ryan,

European Journal of Clinical Investigation

Abstract

Immunotherapy using a FC vaccine and rhIL-12 induced no serious adverse reactions, and provided good therapeutic responses in some of the patients with a brain tumour.

References

	Year	Citations
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. Federica Sallusto, Antonio Lanzavecchia The Journal of Experimental Medicine Dendritic CellImmunologyImmune RegulationSplice VariantImmunologic Mechanism	1994	5.1K
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. Christina M. Celluzzi, José Mayordomo, Walter J. Storkus, The Journal of Experimental Medicine Tumor ImmunologyCancer ImmunosurveillanceCytotoxic TMedicineImmunology	1996	732
Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells Dongshu Chen, Masahiro Kashiwaba, Donald Küfe Nature Medicine Tumor ImmunologyAntitumor ActivityCancer ImmunosurveillanceCarcinoma CellsImmunology	1997	602
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Michael B. Atkins, Michael J. Robertson, Michael S. Gordon, PubMed ImmunologyPharmacotherapyImmunotherapyInflammationHematological Malignancy	1997	590
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. Paul F. Robbins, Mona El‐Gamil, Yongfeng Li, The Journal of Experimental Medicine ImmunologyPathologyAntigen ProcessingBeta-catenin GeneImmunotherapy	1996	547
Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ <i>in vivo</i> Maurice K. Gately, Rajeev R. Warrier, Sharmlla Honasoge, International Immunology Lymphocyte DevelopmentImmunologyImmune RegulationPathologyImmunologic Mechanism	1994	365
Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells Tetsuro Kikuchi, Yasuharu Akasaki, Masaki Irie, Cancer Immunology Immunotherapy VaccinationNeuro-oncologyRadiation OncologyMedicineGlioma Cells	2001	271
Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses David Avigan, Baldev Vasir, Jianlin Gong, Clinical Cancer Research	2004	249
Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Robert J. Motzer, Ashok Rakhit, Lawrence H. Schwartz, PubMed ImmunologyImmunoeditingPharmacotherapyMetronomic ChemotherapyImmunotherapy	1998	231
Vaccination of Glioma Patients with Fusions of Dendritic and Glioma Cells and Recombinant Human Interleukin 12 Tetsuro Kikuchi, Yasuharu Akasaki, Toshiaki Abe, Journal of Immunotherapy ImmunologyPathologyHigh-grade GliomasImmunotherapyGlioma	2004	204

Page 1